CRSP (CRISPR Therapeutics AG)
Insider Trading Activity
Every open-market purchase and sale reported by CRSP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Raju Prasad | Chief Financial Officer | G | — | — |
| 2026-06-09 | Simeon George | Director | A | — | — |
| 2026-06-09 | Sandesh Mahatme | Director | A | — | — |
| 2026-06-09 | Maria Fardis | Director | A | — | — |
| 2026-06-09 | Christian Rommel | Director | A | — | — |
| 2026-06-09 | Katherine A High | Director | A | — | — |
| 2026-06-09 | Briggs Morrison | Director | A | — | — |
| 2026-06-09 | Douglas A Treco | Director | A | — | — |
| 2026-06-09 | Ali Behbahani | Director | A | — | — |
| 2026-06-09 | Harold Edward Fleming | Director | A | — | — |
| 2026-06-09 | John Greene | Director | A | — | — |
| 2026-06-02 | Naimish Patel | Chief Medical Officer | A | — | — |
| 2026-06-02 | JAMES R. KASINGER | General Counsel and Secretary | A | — | — |
| 2026-06-02 | Raju Prasad | Chief Financial Officer | A | — | — |
| 2026-06-01 | Naimish Patel | Chief Medical Officer | MIXED | — | — |
| 2026-03-24 | Naimish Patel | Chief Medical Officer | A | — | — |
| 2026-03-24 | JAMES R. KASINGER | General Counsel and Secretary | MIXED | — | — |
| 2026-03-24 | Raju Prasad | Chief Financial Officer | MIXED | — | — |
| 2026-03-24 | Samarth Kulkarni | Chief Executive Officer | MIXED | — | — |
| 2026-03-17 | JAMES R. KASINGER | General Counsel and Secretary | MIXED | — | — |
| 2026-03-17 | Samarth Kulkarni | Chief Executive Officer | MIXED | — | — |
| 2026-03-17 | Naimish Patel | Chief Medical Officer | MIXED | — | — |
| 2026-03-17 | Raju Prasad | Chief Financial Officer | MIXED | — | — |
| 2026-03-12 | Samarth Kulkarni | Chief Executive Officer | MIXED | — | — |
| 2026-03-12 | JAMES R. KASINGER | General Counsel and Secretary | MIXED | — | — |
| 2026-02-20 | Samarth Kulkarni | Chief Executive Officer | MIXED | — | — |
| 2026-02-20 | JAMES R. KASINGER | General Counsel and Secretary | MIXED | — | — |
| 2026-01-27 | Naimish Patel | Chief Medical Officer | Buy | — | — |
| 2026-01-26 | Raju Prasad | Chief Financial Officer | MIXED | — | — |
| 2026-01-22 | Samarth Kulkarni | Chief Executive Officer | Sell | — | — |
| 2026-01-08 | Raju Prasad | Chief Financial Officer | MIXED | — | — |
| 2025-12-23 | Raju Prasad | Chief Financial Officer | Sell | — | — |
| 2025-12-22 | Samarth Kulkarni | Chief Executive Officer | G | — | — |
| 2025-10-20 | Samarth Kulkarni | Chief Executive Officer | MIXED | — | — |
| 2025-10-15 | JAMES R. KASINGER | General Counsel and Secretary | MIXED | — | — |
| 2025-10-15 | Samarth Kulkarni | Chief Executive Officer | MIXED | — | — |
| 2025-10-03 | Samarth Kulkarni | Chief Executive Officer | A | — | — |
| 2025-10-03 | JAMES R. KASINGER | General Counsel and Secretary | A | — | — |
| 2025-10-03 | Naimish Patel | Chief Medical Officer | A | — | — |
| 2025-10-03 | Raju Prasad | Chief Financial Officer | A | — | — |
| 2025-09-19 | Samarth Kulkarni | Chief Executive Officer | G | — | — |
| 2025-08-19 | Samarth Kulkarni | Chief Executive Officer | MIXED | — | — |
| 2025-08-08 | Douglas A Treco | Director | Buy | — | — |
| 2025-07-17 | Simeon George | Director | Buy | — | — |
| 2025-06-06 | Simeon George | Director | A | — | — |
| 2025-06-06 | Maria Fardis | Director | A | — | — |
| 2025-06-06 | Ali Behbahani | Director | A | — | — |
| 2025-06-06 | Douglas A Treco | Director | A | — | — |
| 2025-06-06 | Harold Edward Fleming | Director | A | — | — |
| 2025-06-06 | Briggs Morrison | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,353,479 | — |
| — | 10%+ Owner | 5,287,087 | — |
| — | Director | 1,261,268 | — |
| — | Director | 645,643 | — |
| — | President | 573,007 | — |
| — | Chief Executive Officer | 341,123 | — |
| — | Director | 238,897 | — |
| — | Director | 148,831 | — |
| — | 10%+ Owner | 117,173 | — |
| — | 10%+ Owner | 115,645 | — |
| — | General Counsel and Secretary | 94,308 | — |
| — | Executive VP, Head of R&D | 64,971 | — |
| — | CBO & COO | 25,026 | — |
| — | Director | 22,000 | — |
| — | Chief Medical Officer | 19,357 | — |
| — | Chief Operating Officer | 19,346 | — |
| — | Chief Financial Officer | 14,815 | — |
| — | Director | 7,500 | — |
| — | Director | 7,000 | — |
| — | Chief Financial Officer | 5,072 | — |
| — | Chief Medical Officer | 4,411 | — |
| — | Chief Financial Officer | 1,891 | — |
| — | Director | 270 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRSP quote page; the site-wide leaderboard is on the insider transactions hub.